Formulation and Evaluation of Dexlansoprazole Delayed Release Capsules
Abstract
Dexlansoprazole (DSP) is a proton pump inhibitor, used in the treatment of gastroesophageal reflex disease (GERD) and ulcer colitis. DSP acts by reducing the quantity of acid in the stomach. DSP is an acid liable drug which can bed egraded in acidic pH of the stomach. A coating method was employed to delay the release of drug in stomach which can prolong the pharmacological action.Sugar spheres (#25, #30) have been used as inert core material for drug coating using the technique of pelletization. Delayed coating, IR coating and ER coating of drug was done by using L-HPC-31, HPMC phthalate-55, Eudragit-RSPO and Eudragit-RLPO respectively. Among the different batches F14 formulation containing 25:75 ratio of immediate release and extended delayed release coating was selected, as retardation of the drug was observed in acidic pH of stomach.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.